Two of the top health care investors at the investment bank SVB Securities and the private equity giant KKR are starting a new biotech investment firm called Enavate Sciences.
Enavate launched Monday with $300 million from Patient Square Capital, a private equity firm started in 2020 by Jim Momtazee, who had helped start the health care investing team at Kohlberg Kravis Roberts & Co. in the early 2000s. Enavate plans to raise an additional $200 million to $300 million this year from family offices and wealthy individual investors, according to its chief executive, James Boylan.